BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2006

View Archived Issues

E1 vaccination evaluated in patients with hepatitis C genotype 1 infection

Read More

Satavaptan improves hyponatremia in cirrhosis patients

Read More

Studies in vivo reveal anti-hepatitis C virus effects of DEBIO-025

Read More

Novel plant-derived CDK inhibitor halts HeLa cell growth

Read More

Adherex begins proof-of-mechanism trial for eniluracil

Read More

Enrollment open in phase I/II study of Chemophase with mitomycin

Read More

PMA submission for 2.25 mm Cypher Stent

Read More

Alexza initiates AZ-003 phase I study

Read More

New preclinical data further elucidate talabostat's dual mechanism of action

Read More

CardioVascular BioTherapeutics begins clinical studies in chronic lower back pain

Read More

Preclinical profile of L-870812 presented

Read More

AstraZeneca presents a new glucokinase activator

Read More

Pre-NDA meeting for AzaSite

Read More

First interim analysis data from phase IIIb mesothelioma study of Onconase

Read More

Treatment begins in pediatric phase III study of nimotuzumab

Read More

Final survival results from phase IIb study of Stimuvax

Read More

AmpliMed studies benzimate in patients with advanced refractory cancer

Read More

Phase III protocol agreed upon for OncoVAX in Stage II colon cancer patients

Read More

ApoB-100-specific ASO more effective than MTTP-specific ASO in lowering cholesterol in mice

Read More

Antifungal BAL-8557 awarded fast track designation

Read More

Wex updates status of Tectin program

Read More

FibroGen licenses oral HIF-PH inhibitors to Astellas

Read More

Pharmacokinetics, safety and activity of pradefovir reported

Read More

PEP-005 Topical gel clears superficial basal cell carcinoma in study

Read More

Cipralex filed in Sweden for obsessive compulsive disorder

Read More

Acomplia recommended for approval in E.U.

Read More

BMS discontinues commercialization of Tequin

Read More

Betaferon recommended for early use in MS patients in E.U.

Read More

Recent patents claim novel therapeutic agents for ocular disorders

Read More

New treatment options reported for disorders associated with blood coagulation

Read More

Novel nicotinic receptor agonist demonstrates preclinical antiinflammatory activity

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing